Novartis Acquires Pikavation for Up to $3 Billion

Novartis AG, the Swiss pharmaceutical giant based in Basel, has agreed to acquire Pikavation Therapeutics, a subsidiary of U.S. biotechnology firm Synnovation Therapeutics, for up to $3 billion, bolstering its oncology pipeline with a promising experimental treatment for breast cancer.

The deal centers on SNV4818, an oral, pan-mutant selective PI3Kα inhibitor designed to target mutated forms of the PI3Kα enzyme found in cancer cells while sparing the normal enzyme in healthy tissue. This approach aims to address a key challenge in treating hormone receptor-positive, human epidermal growth factor receptor 2-negative (HR+/HER2-) metastatic breast cancer, where approximately 40 percent of patients carry PIK3CA mutations associated with poorer prognosis. Unlike existing PI3Kα inhibitors, which block both mutated and wild-type enzymes and often cause significant side effects that limit dosing and combinations with other therapies, SNV4818 seeks to improve tolerability and enable earlier use alongside standard treatments such as fulvestrant and palbociclib.

Preclinical studies have demonstrated strong activity against common PIK3CA mutations and clear selectivity for the mutated...